Abstract

Ligand-induced transcriptional activation of gene expression by nuclear receptors is dependent on recruitment of coactivators as intermediary factors. The present work describes the cloning and characterization of RAP250, a novel human nuclear receptor coactivator. The results of in vitro and in vivo experiments indicate that the interaction of RAP250 with nuclear receptors is ligand-dependent or ligand-enhanced depending on the nuclear receptor and involves only one short LXXLL motif called nuclear receptor box. Transient transfection assays further demonstrate that RAP250 has a large intrinsic glutamine-rich activation domain and can significantly enhance the transcriptional activity of several nuclear receptors, acting as a coactivator. Interestingly, Northern blot and in situ hybridization analyses reveal that RAP250 is widely expressed with the highest expression in reproductive organs (testis, prostate and ovary) and brain. Together, our data suggest that RAP250 may play an important role in mammalian gene expression mediated by nuclear receptor.

Highlights

  • The nuclear receptor (NR)1 superfamily is a large group of structurally related transcription factors that regulate target gene transcription in response to ligands

  • This study describes the structural and functional properties of RAP250, a novel NR coactivator isolated from a mouse embryo library using the yeast two-hybrid system

  • Our results show that RAP250 interacts with multiple members of the NR family in a ligand-dependent manner, indicating that RAP250 is a coactivator of all these NRs

Read more

Summary

Introduction

The nuclear receptor (NR)1 superfamily is a large group of structurally related transcription factors that regulate target gene transcription in response to ligands. CDNA cloning and sequence analysis of this shorter mRNA indicated that it was an alternatively spliced form of RAP250 with an open reading frame encoding a 1070-amino acid-protein and encompassing amino acids 1–971 and 1965– 2063 (data not shown).

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.